Maxiphoto Solid Biosciences ( NASDAQ: SLDB ) is up 15% in premarket trading as it is apparently benefitting from Thursday's announcement of an expanded indication for Sarepta Therapeutics' ( SRPT ) Duchenne muscular dystrophy treatment Elevidys (delandistrogene moxeparvovec). The gene therapy is now also approved for patients who are non-ambulatory . Solid has a gene therapy DMD candidate, SGT-003, which received U.
S. FDA Fast Track designation in December 2023 . SGT-003 uses a proprietary, rationally designed capsid (AAV-SLB101) to deliver a DNA sequence encoding a shortened form of the dystrophin protein (microdystrophin).
More on Solid Biosciences Buy Solid Biosciences: Unpacking Its Main Value Driver Solid Biosciences gets FDA rare pediatric disease status for DMD therapy William Blair starts Solid Biosciences at outperform Seeking Alpha’s Quant Rating on Solid Biosciences Historical earnings data for Solid Biosciences.
